GSP Crop Science Ltd
GSPCROPGSP Crop Science Ltd is strength at full price. The numbers are improving — and a P/E at the 91st percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 91st percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (19 weeks in) while the P/E sits at the 91st percentile of its own 0-year range. Underneath, the last four quarters read improving — profit +13.0% year on year, and 128% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
GSP Crop Science Ltd trades at ₹596, in a confirmed uptrend and 19 weeks into that stage. That is +40.7% against its own 200-day average. It sits at 99% of a 52-week range of ₹394 to ₹598. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.
Today the stock is in a confirmed uptrend — week 19 of stage 2, confirmed. At ₹596 it trades +40.7% versus its 200-day average and sits at 99% of its 52-week range (₹394–₹598).
Against the market, two honest reads. Cumulative: over the last 4 months the stock moved +41% while the NIFTY 500 moved +3% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
GSP Crop Science Ltd trades at 26.5× P/E, at the pricey end of its own range (91st percentile). Its long-run median P/E is 20.0×, measured across 0.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 26.5× is at the pricey end of its own range (91st percentile), against a long-run median of 20.0× measured over 0.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
GSP Crop Science Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +17.9% | +8.0% | +7.1% | — |
| Profit | +15.9% | +62.8% | +6.9% | — |
| EPS | +0.0% | −35.3% | −38.0% | — |
4-Factor Sector Score
50.3/100 — rank 11 of 24 in Pesticides/Agrochemicals · 63% evidence confidence
GSP Crop Science Ltd scores 50.3 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 11. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 18.1 + 12.8 + 9.4 + 10 = 50.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
GSP Crop Science Ltd reported ₹386 Cr of revenue in the Jun 26 quarter, +2.4% year on year. That is the 2nd straight quarter of year-on-year growth. Over 6 years it has compounded at 9.0% a year. The last full year, FY26, came in at ₹1,517 Cr. The last four reported quarters add to ₹1,525 Cr.
FY26 revenue came in at ₹1,517 Cr (+17.9% on the year), capping 6 years at 9.0% compound. The latest quarter (Jun 26) printed ₹386 Cr, +2.4% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +10.2% growth against the decade's 9.0% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
GSP Crop Science Ltd's operating margin is 11.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 7 fiscal years the operating margin has ranged 7.0% to 12.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 11.0%, +0.0 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 7.0%–12.0%, and FY26's 12.0% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −0.2 pp year on year while gross margin went +2.4 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
GSP Crop Science Ltd earned ₹26.0 Cr of net profit in the Jun 26 quarter, +13.0% year on year. Full-year FY26 profit was ₹95.0 Cr. The 6-year compound rate is 28.6%. That is 6.7% of the quarter's revenue. The same quarter a year earlier earned ₹23.0 Cr.
Jun 26 profit was ₹26.0 Cr, +13.0% year on year. On the full year, FY26 printed ₹95.0 Cr (+15.9%), and the 6-year compound rate is 28.6%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 128% of GSP Crop Science Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹59.0 Cr of operating cash against ₹95.0 Cr of profit. After ₹61.0 Cr of capital spending, ₹−2.0 Cr was left as free cash.
FY26: operating cash of ₹59.0 Cr against reported profit of ₹95.0 Cr, leaving free cash of ₹−2.0 Cr after ₹61.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 128% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 128%: the cash cycle stretched 31 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 2.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
GSP Crop Science Ltd's cash conversion cycle runs 121 days in FY26, up from 90 days in FY21. Capital spending ran ₹183 Cr over the last 3 years. At FY26 sales of ₹1,517 Cr each day of that cycle holds about ₹4.2 Cr, so roughly ₹503 Cr sits inside the business at any moment.
FY26: debtors at 133 days, inventory at 136 days — roughly 4.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 121 days, looser than FY21's 90.
The full loop: cash goes out to suppliers and production on day 0; stock waits 136 days to sell; customers pay about 133 days after that; and suppliers themselves are paid at 147 days — netting out to the 121-day cycle.
In money terms: at FY26 sales of ₹1,517 Cr, each day of the cycle holds about ₹4.2 Cr — so the 121-day loop keeps roughly ₹503 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹183 Cr over the last 3 fiscal years against ₹73.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹48.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
GSP Crop Science Ltd earns a ROCE of 19% in FY26. That is up from a trough of 8% in FY23. Return on invested capital clears the cost of that capital by +1.4 percentage points, so growth here adds value rather than only size. The wiring behind it is 6.3% net margin on 0.98× asset turns.
FY26 ROCE is 19%, recovered from a FY23 trough of 8% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 6.3% net margin × 0.98× asset turns × 2.00× balance-sheet leverage ≈ 12.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 13.4% − 12.0% = a +1.4 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
GSP Crop Science Ltd carries total debt of ₹262 Cr against shareholder equity of ₹770 Cr as of Mar 26, a debt-to-equity of 0.34. On the annual view that ratio went from 0.66 in FY25 to 0.34 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹262 Cr against shareholder equity of ₹770 Cr — a debt-to-equity of 0.34. On the annual view, debt-to-equity went from 0.66 (FY25) to 0.34 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of GSP Crop Science Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
GSP Crop Science Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Titan Biotech LtdTITANBIO | 73.2/100Favorable setup76% evidence | 30.1/35 Revenue 37.7% · PAT 59.1% · OPM change 2 pp 95% evidence | 20.1/25 ROCE 22.8% · OPM 21% 76% evidence | 6.0/20 P/E 48.7× · PEG — 50% evidence | 17.0/20 RS sector 103.8% · RS bench 85% · 1Y 212.3%8 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 30.1 + 20.1 + 6 + 17 = 73.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Bayer CropScience LtdBAYERCROP | 71.0/100Favorable setup91% evidence | BASING | 22.5/35 Revenue -2.8% · PAT 23.8% · OPM change 2 pp 95% evidence | 20.8/25 ROCE 29.1% · OPM 20% 95% evidence | 14.7/20 P/E 24.8× · PEG 1.28 100% evidence | 13.0/20 RS sector 12.3% · RS bench -14% · 1Y -27.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 22.5 + 20.8 + 14.7 + 13 = 71 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Sharda Cropchem LtdSHARDACROP | 64.1/100Mixed-positive evidence97% evidence | ASLEEP | 23.6/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 95% evidence | 19.3/25 ROCE 30.2% · OPM 17% 95% evidence | 18.7/20 P/E 11.3× · PEG 0.26 100% evidence | 2.5/20 RS sector -14.9% · RS bench -17% · 1Y -20.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 19.3 + 18.7 + 2.5 = 64.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.9% and the one-year return is -20.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 4Punjab Chemicals & Crop Protection LtdPUNJABCHEM | 61.6/100Mixed-positive evidence81% evidence | FADING | 23.0/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence | 18.1/25 ROCE 18.6% · OPM 12% 95% evidence | 11.6/20 P/E 20× · PEG — 50% evidence | 8.9/20 RS sector -3.8% · RS bench -6.7% · 1Y -15.4%1 of 10 weeks ahead 70% evidence |
| Exact sum: 23 + 18.1 + 11.6 + 8.9 = 61.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Dharmaj Crop Guard LtdDHARMAJ | 60.7/100Mixed-positive evidence74% evidence | BASING | 20.7/35 Revenue 8.5% · PAT 13.2% · OPM change 1 pp 95% evidence | 15.2/25 ROCE 16.4% · OPM 15% 95% evidence | 10.9/20 P/E 15.2× · PEG — 15% evidence | 13.9/20 RS sector 7.7% · RS bench -1.3% · 1Y -17.1%2 of 10 weeks ahead 70% evidence |
| Exact sum: 20.7 + 15.2 + 10.9 + 13.9 = 60.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Advance Agrolife LtdADVANCE | 57.2/100Mixed-positive evidence60% evidence | TURNING | 21.5/35 Revenue 48.4% · PAT 81.5% · OPM change 1 pp 95% evidence | 14.9/25 ROCE 19.3% · OPM 11% 95% evidence | 10.8/20 P/E 15.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 10 weeks ahead 0% evidence |
| Exact sum: 21.5 + 14.9 + 10.8 + 10 = 57.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Bhagiradha Chemicals & Industries LtdBHAGCHEM | 56.8/100Mixed-positive evidence100% evidence | TURNING | 28.8/35 Revenue 33.7% · PAT 100% · OPM change 9 pp 100% evidence | 7.0/25 ROCE 4.5% · OPM 16% 100% evidence | 1.6/20 P/E 137× · PEG 8.06 100% evidence | 19.4/20 RS sector 20.5% · RS bench 16.9% · 1Y 0.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 28.8 + 7 + 1.6 + 19.4 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8India Pesticides LtdIPL | 53.6/100Mixed-positive evidence81% evidence | ASLEEP | 20.0/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence | 13.7/25 ROCE 16.6% · OPM 14% 95% evidence | 14.1/20 P/E 15× · PEG — 50% evidence | 5.8/20 RS sector -9.6% · RS bench -18.6% · 1Y -38%3 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 13.7 + 14.1 + 5.8 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Rallis India LtdRALLIS | 51.3/100Mixed-positive evidence91% evidence | ASLEEP | 19.8/35 Revenue 4.4% · PAT 24.4% · OPM change 2 pp 95% evidence | 10.6/25 ROCE 14.1% · OPM 18% 95% evidence | 11.2/20 P/E 18.1× · PEG 2.15 100% evidence | 9.7/20 RS sector 0.8% · RS bench -21% · 1Y -40.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.8 + 10.6 + 11.2 + 9.7 = 51.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Jubilant Ingrevia LtdJUBLINGREA | 51.1/100Mixed-positive evidence93% evidence | FADING | 18.6/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.4% · OPM 15% 100% evidence | 6.1/20 P/E 36.9× · PEG 2.41 65% evidence | 15.8/20 RS sector 10.5% · RS bench 7.3% · 1Y 5.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 10.6 + 6.1 + 15.8 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11GSP Crop Science Ltdthis pageGSPCROP | 50.3/100Mixed-positive evidence63% evidence | BREAKING OUT | 18.1/35 Revenue 16.1% · PAT 36.1% · OPM change 0 pp 100% evidence | 12.8/25 ROCE 19% · OPM 11% 100% evidence | 9.4/20 P/E 26.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 5 weeks ahead 0% evidence |
| Exact sum: 18.1 + 12.8 + 9.4 + 10 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12NACL Industries LtdNACLIND | 47.3/100Mixed-negative evidence100% evidence | ASLEEP | 28.9/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence | 4.0/25 ROCE 8.1% · OPM 11% 100% evidence | 3.7/20 P/E 151× · PEG 2.02 100% evidence | 10.7/20 RS sector -3.5% · RS bench -6.8% · 1Y -39.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 28.9 + 4 + 3.7 + 10.7 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Sumitomo Chemical India LtdSUMICHEM | 45.8/100Mixed-negative evidence94% evidence | BREAKING OUT | 12.4/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence | 19.0/25 ROCE 22.1% · OPM 22% 100% evidence | 3.8/20 P/E 49.4× · PEG 4 100% evidence | 10.6/20 RS sector -5.8% · RS bench 17.2% · 1Y -2.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 19 + 3.8 + 10.6 = 45.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 14Bharat Rasayan LtdBHARATRAS | 45.1/100Mixed-negative evidence87% evidence | BASING | 10.5/35 Revenue -5.2% · PAT 3.6% · OPM change -3 pp 95% evidence | 14.6/25 ROCE 17.4% · OPM 15% 95% evidence | 14.3/20 P/E 14.8× · PEG — 50% evidence | 5.7/20 RS sector -29.3% · RS bench -32% · 1Y -50.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 14.6 + 14.3 + 5.7 = 45.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15Meghmani Organics LtdMOL | 45.1/100Mixed-negative evidence74% evidence | TURNING | 20.8/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence | 7.8/25 ROCE 6.7% · OPM 18% 95% evidence | 9.5/20 P/E 25× · PEG — 15% evidence | 7.0/20 RS sector -32% · RS bench 2.7% · 1Y -26.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 7.8 + 9.5 + 7 = 45.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Excel Industries LtdEXCELINDUS | 43.9/100Mixed-negative evidence74% evidence | BASING | 12.0/35 Revenue 5.5% · PAT -20.4% · OPM change 0 pp 95% evidence | 10.3/25 ROCE 6.1% · OPM 14% 95% evidence | 10.4/20 P/E 17.8× · PEG — 15% evidence | 11.2/20 RS sector -2.1% · RS bench 0.4% · 1Y -13.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12 + 10.3 + 10.4 + 11.2 = 43.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Epigral LtdEPIGRAL | 42.0/100Mixed-negative evidence94% evidence | ASLEEP | 7.1/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence | 14.6/25 ROCE 15.5% · OPM 25% 100% evidence | 15.6/20 P/E 17.5× · PEG 0.43 100% evidence | 4.7/20 RS sector -31.1% · RS bench -15.3% · 1Y -40.2%5 of 10 weeks ahead 70% evidence |
| Exact sum: 7.1 + 14.6 + 15.6 + 4.7 = 42 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Dhanuka Agritech LtdDHANUKA | 41.2/100Mixed-negative evidence100% evidence | ASLEEP | 6.3/35 Revenue -5.6% · PAT -12.1% · OPM change -4 pp 100% evidence | 16.3/25 ROCE 23.8% · OPM 12% 100% evidence | 11.6/20 P/E 16.8× · PEG 1.72 100% evidence | 7.0/20 RS sector -13% · RS bench -16.1% · 1Y -36.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 6.3 + 16.3 + 11.6 + 7 = 41.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Astec Lifesciences LtdASTEC | 40.4/100Mixed-negative evidence69% evidence | ASLEEP | 23.7/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence | 3.3/25 ROCE -5.4% · OPM -0.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.4/20 RS sector -14.5% · RS bench -17.3% · 1Y -26.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 3.3 + 10 + 3.4 = 40.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.5% and the one-year return is -26.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 20UPL LtdUPL | 40.0/100Mixed-negative evidence91% evidence | ASLEEP | 16.9/35 Revenue 12.9% · PAT 98.4% · OPM change -2 pp 74% evidence | 8.3/25 ROCE 10.1% · OPM 13% 100% evidence | 12.5/20 P/E 24× · PEG 0.5 100% evidence | 2.3/20 RS sector -15.7% · RS bench -18% · 1Y -18.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 8.3 + 12.5 + 2.3 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Insecticides India LtdINSECTICID | 38.1/100Mixed-negative evidence87% evidence | ASLEEP | 10.4/35 Revenue 1.3% · PAT -16.7% · OPM change -1 pp 95% evidence | 11.0/25 ROCE 15.8% · OPM 11% 95% evidence | 11.3/20 P/E 14.7× · PEG — 50% evidence | 5.4/20 RS sector -7% · RS bench -9.9% · 1Y -35.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 10.4 + 11 + 11.3 + 5.4 = 38.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22P I Industries LtdPIIND | 37.7/100Mixed-negative evidence94% evidence | ASLEEP | 4.4/35 Revenue -16.6% · PAT -27.8% · OPM change -5 pp 100% evidence | 13.9/25 ROCE 15% · OPM 22% 100% evidence | 10.6/20 P/E 35× · PEG 1.71 100% evidence | 8.8/20 RS sector -0.9% · RS bench -22.6% · 1Y -36.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 4.4 + 13.9 + 10.6 + 8.8 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Best Agrolife LtdBESTAGRO | 34.6/100Adverse evidence87% evidence | TURNING | 7.7/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence | 9.2/25 ROCE 5.2% · OPM 20% 95% evidence | 7.0/20 P/E 22.6× · PEG — 50% evidence | 10.7/20 RS sector -4.5% · RS bench -7.7% · 1Y -37.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 7.7 + 9.2 + 7 + 10.7 = 34.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Heranba Industries LtdHERANBA | 25.8/100Adverse evidence65% evidence | ASLEEP | 12.0/35 Revenue 13.1% · PAT -80% · OPM change -2.7 pp 62% evidence | 1.2/25 ROCE -1.6% · OPM -7% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.6/20 RS sector -25.3% · RS bench -28.1% · 1Y -51.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 1.2 + 10 + 2.6 = 25.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is GSP Crop Science Ltd's share price today?
GSP Crop Science Ltd trades at ₹596. The company is valued at ₹2,774 Cr. The stock sits at 99% of its 52-week range of ₹394–₹598, +40.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 19 weeks in. — as of 14 August 2026.
What were GSP Crop Science Ltd's latest quarterly results?
GSP Crop Science Ltd reported revenue of ₹386 Cr and net profit of ₹26.0 Cr for the Jun 26 quarter. Revenue rose 2.4% and profit rose 13.0% year on year. Earnings per share were ₹5.67. The operating margin was 11.0%, 0.0 pp higher than a year earlier. — as of 14 August 2026.
What is GSP Crop Science Ltd's revenue?
GSP Crop Science Ltd reported revenue of ₹386 Cr in the Jun 26 quarter, +2.4% year on year. For the full FY26 fiscal year, revenue was ₹1,517 Cr (+17.9%). Over the last 6 years revenue compounded at 9.0% a year. — as of 14 August 2026.
What is GSP Crop Science Ltd's profit?
GSP Crop Science Ltd earned ₹26.0 Cr of net profit in the Jun 26 quarter, +13.0% year on year. Full-year FY26 profit was ₹95.0 Cr. The operating margin ran 11.0% in the latest quarter. — as of 14 August 2026.
What is GSP Crop Science Ltd's market cap?
GSP Crop Science Ltd's market capitalisation is ₹2,774 Cr at a share price of ₹596. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 14 August 2026.
What is GSP Crop Science Ltd's P/E ratio?
GSP Crop Science Ltd trades at a P/E of 26.5×, at the 91st percentile of its own 0-year range, against a long-run median of 20.0×. This is a comparison with the stock's own history, not a value call — as of 14 August 2026.
Does GSP Crop Science Ltd pay a dividend?
Yes — GSP Crop Science Ltd's dividend payout was 5% of profit in FY26, and it recorded a payout in each of its last 7 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 14 August 2026.
Is GSP Crop Science Ltd overvalued?
On its own history, GSP Crop Science Ltd looks expensive: its P/E of 26.5× sits at the 91st percentile of its 0-year range (long-run median 20.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 14 August 2026.
Is GSP Crop Science Ltd growing?
Yes — GSP Crop Science Ltd is growing: latest-quarter revenue +2.4% year on year, profit +13.0%, and the margin +0.0 pp at 11.0%. The 6-year compound rates are 9.0% (revenue) and 28.6% (profit). The earnings engine currently reads: improving — as of 14 August 2026.
How is GSP Crop Science Ltd performing?
GSP Crop Science Ltd is in a confirmed uptrend, 19 weeks in. Its latest quarter's revenue rose 2.4% and profit rose 13.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 14 August 2026.
Is GSP Crop Science Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 19 of stage 2), trading +40.7% versus its 200-day average and at 99% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 14 August 2026.
Is GSP Crop Science Ltd beating the market?
On recent form, yes — GSP Crop Science Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 4 months the stock moved +41% against the NIFTY 500's +3% — ahead of the index over the full window. — as of 14 August 2026.
Will GSP Crop Science Ltd's share price go up?
This page publishes no price forecast for GSP Crop Science Ltd. What it measures instead: the share price is ₹596, the price is in a confirmed uptrend 19 weeks in. Its P/E of 26.5× sits at the 91st percentile of its own 0-year range. — as of 14 August 2026.
Who owns GSP Crop Science Ltd?
Promoters hold 71.7% of GSP Crop Science Ltd, foreign institutions 9.2%, domestic institutions 0.4% and the public 18.7% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 14 August 2026.
Does GSP Crop Science Ltd have too much debt?
It is moderate — GSP Crop Science Ltd's debt-to-equity is 0.34, and operating profit covers the interest bill 5×. FY26 borrowings were ₹262 Cr against equity of ₹772 Cr. Read the returns on this page with that leverage in mind — as of 14 August 2026.
What is GSP Crop Science Ltd's capex?
GSP Crop Science Ltd spent ₹183 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹61.0 Cr, with ₹48.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 14 August 2026.
What is GSP Crop Science Ltd's cash flow?
GSP Crop Science Ltd generated ₹59.0 Cr of operating cash flow in FY26 and ₹−2.0 Cr of free cash flow after ₹61.0 Cr of capital spending. Reported profit that year was ₹95.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 14 August 2026.
Is GSP Crop Science Ltd's profit real cash?
Yes — over the last 3 fiscal years, 128% of GSP Crop Science Ltd's reported profit arrived as operating cash. Though the latest year ran at 62% — the trend is the thing to watch. In FY26, operating cash was ₹59.0 Cr against reported profit of ₹95.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 14 August 2026.
Where is GSP Crop Science Ltd in its business cycle?
GSP Crop Science Ltd's FY26 operating margin was 12.0%, against a 7-year band of 7.0%–12.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 11.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 14 August 2026.
What could break the GSP Crop Science Ltd story?
The sharpest disagreement: the engine is strong, but at the 91st percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 14 August 2026.
Is GSP Crop Science Ltd a stock worth studying right now?
This is not investment advice. The machine read: GSP Crop Science Ltd is strength at full price. The numbers are improving — and a P/E at the 91st percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 14 August 2026.